Evidence map›Paper›PMID 37161496›Full record

ArticleAIDS research and therapy2023

Serum E-selectin and endothelial cell-specific Molecule-1 levels among people living with HIV on long term ART in Uganda: a pilot cross-sectional study.

Andrew Weil Semulimi, Charles Batte, Alice Bayiyana, Mariam Nakabuye, John Mukisa, Barbara Castelnuovo, Rosalind Parkes Ratanshi, Bruce J Kirenga, Isaac Ssinabulya

Open access · goldAbstract read
In one paragraph

Article in AIDS research and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Andrew Weil SemulimiLung Institute, Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. andrewweil89@gmail.com.
Charles BatteLung Institute, Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Alice BayiyanaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Mariam NakabuyeLung Institute, Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
John MukisaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Barbara CastelnuovoInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Rosalind Parkes RatanshiInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Bruce J KirengaLung Institute, Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Isaac SsinabulyaDepartment of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Makerere University · UGInfectious Diseases Institute · UGUniversity of Cambridge · GB

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
Training in noncommunicable diseases epidemiological, data science and Implementation Science research to strengthen evidence-based interventions, policy and control in Uganda.D43TW011401 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI Charles Batte, William Checkley · 2019 to 2026
$1.8M
FIC NIH HHS D43 TW009771FIC NIH HHS D43 TW011401Fogarty International Centre, National Institutes of Health D43TW009771Fogarty International Centre, National Institutes of Health D43TW011401NIAID NIH HHS P30 AI036214
6 · The paper itself

Abstract

backgroundProlonged exposure to HIV and anti-retroviral therapy (ART) has been linked with endothelial cell activation which subsequently predisposes people living with HIV (PLWH) to cardiovascular diseases. Serum biomarkers of endothelial cell activation such as E-Selectin and endothelial cell-specific molecule-1 (ESM-1) could aid in early detection of PLWH at a risk of cardiovascular diseases. However, there is a paucity of data on these biomarkers like E-selectin and endothelial cell-specific molecule-1 (ESM-1) among PLWH on long term ART (≥ 10 years) in Uganda. The aim of this study is to determine the serum levels of these biomarkers in this population.

methodsThis was a cross-sectional study where we randomly sampled 73 stored serum samples of PLWH who were enrolled in the Infectious Diseases Institute (IDI) ART long term (ALT cohort). We measured serum levels of E-selectin and ESM-1 by ELISA. Data was summarized using median and interquartile range. Inferential statistics were performed to determine predictors of elevated levels of E-selectin.

resultsOf the 73 samples analyzed, 38 (52.1%) were from female participants. The mean age was 54 ± 9.0 years. Twenty participants (27.4%) had a history of smoking while 52 (71.2%) had a history of alcohol intake. Twenty-five (34.3%) of the participants were overweight whereas 4 (5.6%) were obese. Fifty-four (74%) had an undetectable viral load (≤ 0 copies/ml) and the mean duration of ART at the time of sampling (2014/2015) was 10.4 ± 0.4 years. While serum levels of ESM-1 were not detectable in any of our samples, the median E-selectin levels was 147.6 μm/L ranging from 8.44 μm/L and 1,979.36 μm/L. Sixty-seven participants (91.8%) had elevated levels of E-selectin (> 39 μm/L). CD4 count > 500 cells/µl compared to lower counts was a predictor of elevated levels of E-Selectin (adjusted Odd Ratio 12.5, 95% CI (1.03 - 149.95, p < 0.05).

conclusionsThe majority (91.8%) of PLWH on long term ART had elevated levels of E-selectin. Having high CD4 count (> 500 cells/µl) was predictive of elevated levels of E-Selectin. Future work should longitudinally assess the trend of levels of E-selectin and ESM-1 while assessing for cardiovascular diseases endpoint.

Indexed as

Cardiovascular DiseasesHIV InfectionsCross-Sectional StudiesEndothelial CellsE-SelectinFemaleHumansMiddle AgedUgandaE-SelectinEndothelial activationE-SelectinLong-term antiretroviral therapy

Identifiers

PMID37161496
PMCPMC10169468
OpenAlexW4376132481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.